SUPERNUS PHARMACEUTICALS, INC. (SUPN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
60/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseSUPN / S&P -10.02% / 15.20% |
WinSUPN / S&P 24.85% / 15.00% |
LoseSUPN / S&P -266.96% / 50.40% |
| 2026-Q12/3 |
WinSUPN / S&P 4.00% / -4.33% |
WinSUPN / S&P 16.29% / 11.30% |
LoseSUPN / S&P -145.95% / 27.70% |
| 2025-Q41/3 |
WinSUPN / S&P 4.00% / 2.65% |
LoseSUPN / S&P 8.63% / 9.00% |
LoseSUPN / S&P -151.52% / 13.40% |
| 2025-Q31/3 |
WinSUPN / S&P 51.62% / 8.12% |
LoseSUPN / S&P 4.54% / 4.61% |
LoseSUPN / S&P -131.78% / 13.45% |
| 2025-Q22/3 |
LoseSUPN / S&P -3.76% / 10.94% |
WinSUPN / S&P 5.55% / 4.83% |
WinSUPN / S&P 1177.78% / 10.63% |
| 2025-Q11/3 |
LoseSUPN / S&P -9.43% / -4.27% |
WinSUPN / S&P 11.82% / 4.98% |
LoseSUPN / S&P -482.76% / 10.57% |
| 2024-Q42/3 |
WinSUPN / S&P 15.97% / 2.41% |
WinSUPN / S&P 8.94% / 5.25% |
LoseSUPN / S&P -7609281930405188608.00% / 6.15% |
| 2024-Q33/3 |
WinSUPN / S&P 16.56% / 5.89% |
WinSUPN / S&P 6.79% / 5.89% |
WinSUPN / S&P 167.50% / 6.11% |
| 2024-Q20/3 |
LoseSUPN / S&P -21.58% / 4.28% |
LoseSUPN / S&P -0.61% / 5.38% |
LoseSUPN / S&P -87.50% / 5.12% |
| 2024-Q11/3 |
WinSUPN / S&P 17.86% / 10.56% |
LoseSUPN / S&P -10.64% / 5.71% |
LoseSUPN / S&P -132.95% / 5.59% |
| 2023-Q40/3 |
LoseSUPN / S&P 4.97% / 11.69% |
LoseSUPN / S&P -8.95% / 6.81% |
LoseSUPN / S&P -100.00% / 7.78% |
| 2023-Q30/3 |
LoseSUPN / S&P -8.28% / -3.27% |
LoseSUPN / S&P -7.35% / 7.52% |
LoseSUPN / S&P -37.50% / -5.03% |
| 2023-Q20/3 |
LoseSUPN / S&P -17.03% / 8.74% |
LoseSUPN / S&P 0.62% / 9.50% |
LoseSUPN / S&P -28.71% / -8.57% |
| 2023-Q11/3 |
LoseSUPN / S&P 1.57% / 7.50% |
WinSUPN / S&P 11.17% / 10.77% |
LoseSUPN / S&P -32.31% / -15.69% |
| 2022-Q42/3 |
LoseSUPN / S&P 5.38% / 7.56% |
WinSUPN / S&P 15.09% / 11.88% |
WinSUPN / S&P 4.08% / -17.99% |
| 2022-Q32/3 |
WinSUPN / S&P 17.05% / -4.88% |
WinSUPN / S&P 16.78% / 13.47% |
LoseSUPN / S&P -57.62% / -1.41% |
| 2022-Q21/3 |
WinSUPN / S&P -10.52% / -16.10% |
LoseSUPN / S&P 10.35% / 13.71% |
LoseSUPN / S&P -45.41% / 11.04% |
| 2022-Q11/3 |
WinSUPN / S&P 10.84% / -4.60% |
LoseSUPN / S&P 8.09% / 15.97% |
LoseSUPN / S&P -37.20% / 42.23% |
| 2021-Q40/3 |
LoseSUPN / S&P 9.34% / 11.03% |
LoseSUPN / S&P 11.41% / 15.00% |
LoseSUPN / S&P -58.47% / 96.40% |
| 2021-Q31/3 |
LoseSUPN / S&P -13.38% / 0.58% |
WinSUPN / S&P 18.23% / 10.77% |
LoseSUPN / S&P -37.34% / 69.42% |
| 2021-Q22/3 |
WinSUPN / S&P 17.61% / 8.55% |
WinSUPN / S&P 34.57% / 6.58% |
LoseSUPN / S&P -16.29% / 51.81% |
| 2021-Q11/3 |
LoseSUPN / S&P 4.05% / 6.17% |
WinSUPN / S&P 38.31% / -1.06% |
LoseSUPN / S&P -4.61% / 7.39% |
| 2020-Q43/3 |
WinSUPN / S&P 20.73% / 12.15% |
WinSUPN / S&P 32.50% / -3.72% |
WinSUPN / S&P 11.85% / -33.42% |
| 2020-Q32/3 |
LoseSUPN / S&P -12.25% / 8.93% |
WinSUPN / S&P 16.91% / -2.04% |
WinSUPN / S&P 22.34% / -27.10% |
| 2020-Q23/3 |
WinSUPN / S&P 32.02% / 20.54% |
WinSUPN / S&P 3.71% / -0.46% |
WinSUPN / S&P 13.33% / -27.11% |
| 2020-Q11/3 |
LoseSUPN / S&P -24.16% / -19.60% |
LoseSUPN / S&P -0.42% / 3.47% |
WinSUPN / S&P 13.61% / -14.75% |
| 2019-Q40/3 |
LoseSUPN / S&P -13.68% / 9.07% |
LoseSUPN / S&P -3.95% / 5.36% |
LoseSUPN / S&P 2.43% / 2.99% |
| 2019-Q32/3 |
LoseSUPN / S&P -16.95% / 1.70% |
WinSUPN / S&P 7.63% / 5.02% |
WinSUPN / S&P 7.07% / 0.21% |
| 2019-Q22/3 |
LoseSUPN / S&P -5.57% / 4.30% |
WinSUPN / S&P 15.45% / 6.64% |
WinSUPN / S&P 21.12% / 8.65% |
| 2019-Q12/3 |
LoseSUPN / S&P 5.48% / 13.65% |
WinSUPN / S&P 23.09% / 8.12% |
WinSUPN / S&P 40.44% / 14.29% |
| 2018-Q42/3 |
LoseSUPN / S&P -34.02% / -13.52% |
WinSUPN / S&P 39.03% / 9.05% |
WinSUPN / S&P 94.34% / 18.23% |
| 2018-Q32/3 |
LoseSUPN / S&P -15.87% / 7.71% |
WinSUPN / S&P 41.07% / 10.21% |
WinSUPN / S&P 70.37% / 19.06% |
| 2018-Q22/3 |
WinSUPN / S&P 30.68% / 3.43% |
WinSUPN / S&P 43.81% / 9.03% |
LoseSUPN / S&P -18.27% / 14.46% |
| 2018-Q12/3 |
WinSUPN / S&P 14.93% / -0.76% |
WinSUPN / S&P 46.88% / 7.68% |
LoseSUPN / S&P -25.68% / 12.46% |
| 2017-Q41/3 |
LoseSUPN / S&P -0.38% / 6.64% |
WinSUPN / S&P 39.99% / 7.03% |
LoseSUPN / S&P -38.37% / 13.82% |
| 2017-Q31/3 |
LoseSUPN / S&P -7.19% / 4.48% |
WinSUPN / S&P 40.33% / 5.68% |
LoseSUPN / S&P -31.21% / 17.57% |
| 2017-Q23/3 |
WinSUPN / S&P 37.70% / 3.09% |
WinSUPN / S&P 41.19% / 4.83% |
WinSUPN / S&P 319.15% / 17.74% |
| 2017-Q13/3 |
WinSUPN / S&P 23.96% / 6.07% |
WinSUPN / S&P 41.00% / 3.67% |
WinSUPN / S&P 471.87% / 13.32% |
| 2016-Q42/3 |
LoseSUPN / S&P 2.10% / 3.82% |
WinSUPN / S&P 46.37% / 2.09% |
WinSUPN / S&P 561.54% / 7.05% |
| 2016-Q32/3 |
WinSUPN / S&P 21.40% / 3.85% |
WinSUPN / S&P 45.77% / 0.20% |
LoseSUPN / S&P -703.85% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SUPN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -2.06% | 20.78% |
| Annualized return | -2.06% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SUPN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 58.96% | 83.14% |
| Annualized return | 9.71% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | SUPN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 100.59% | 319.30% |
| Annualized return | 7.21% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |